News

First non-melanoma skin cancer patients treated with the Rhenium-SCT® in Germany

The first Rhenium-SCT® treatment was accomplished by the interregional professional association for nuclear medicine in Hanau

October 4, 2019; Hanau, Germany – OncoBeta®, a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), announced today, that Dr. Lutz-Hendrik Holle, Medical Director of the interregional professional association for nuclear medicine in Hanau, has accomplished the first Rhenium-SCT® (Skin Cancer Therapy) treatment in Germany.

Read More

OncoBeta® chosen as a 2019 Red Herring North America Top 100 Winner

New recognition of OncoBeta’s success in developing and providing an innovative therapy for non-melanoma skin cancer patients.

July 5, 2019; Pasadena, U.S. – OncoBeta®, a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), announced today, that it was honored as a Red Herring Top 100 North America Award winner recognizing the continent’s most exciting and innovative private technology companies. After being recognized with the Red Herring Top 100 Europe Award earlier this year, this is now the second recognition obtained by Red Herring.

Read More

Rhenium-SCT® (SCT= Skin Cancer Therapy) now being offered in Hanau, Germany

The interregional professional association for nuclear medicine in Hanau is the first treatment center in Germany offering Rhenium-SCT® for the treatment of non-melanoma skin cancer

May 13 2019, Garching n. Munich, Germany– OncoBeta® GmbH, a commercial stage Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), is pleased to announce that the interregional professional association for nuclear medicine in Hanau now offers the Rhenium-SCT ® (SCT= Skin Cancer Therapy) as the first treatment center in Germany.

Read More

OncoBeta ® GmbH Named Among ‘30 Ethical Companies of the Year 2019’ by The Silicon Review Magazine

Recognition for OncoBeta`s mission to give non-melanocytic skin cancer patients back their quality of life.

April 05, 2019; Garching near Munich, Germany – OncoBeta® GmbH, a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non- Melanocytic Skin Cancer (NMSC) proudly announced today that the Silicon Review Magazine has named it among the 30 Ethical Companies of the Year 2019.

Read More

OncoBeta® chosen as a 2019 Red Herring Top 100 Europe Winner

Recognition of OncoBeta’s success in developing and providing an innovative therapy for patients suffering from non-melanocytic skin cancer

Feb 20, 2019; Amsterdam, Netherlands – OncoBeta® GmbH, a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), announced today, that it was honored as a Red Herring Top 100 Europe Award winner recognizing Europe’s leading private companies, celebrating these startups’ innovations and technologies across their respective industries.

Read More

OncoBeta® GmbH is listed as one of the Top 20 MedTech Outlook Solution Providers in Europe

Garching n. Munich, Germany, (January 10, 2019) – OncoBeta® GmbH, a commercial stage Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), is proud to announce that it is listed as one of the Top 20 MedTech Solution Providers in Europe in 2018 by MedTech Outlook.

Read More

First Non-Melanocytic Skin Cancer Patients treated with Rhenium-SCT in South Africa

University of Pretoria Prof. Mike Sathekge is First in South Africa to Treat Non-Melanocytic Skin Cancer Patients with Rhenium-SCT®

OncoBeta® GmbH, a commercial stage Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), announced today that Prof. Mike Sathekge from the University of Pretoria, Steve Biko Academic Hospital Nuclear Medical department and his clinical team has treated the first non-melanocytic skin cancer patients in South Africa with the innovative Rhenium-SCT® skin cancer treatment System.

Read More

OncoBeta’s Rhenium-SCT® for Non-Melanoma Skin Cancer to start in South Africa

TAUTOMER / NATIVA the official Rhenium-SCT® (Skin Cancer Therapy) Distributor for Continental Africa

OncoBeta GmbH®, a commercial stage Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), is pleased to announce that it has entered an exclusive distribution agreement with Tautomer (PTY) LTD / Nativa (PTY) LTD of South Africa to start Rhenium-SCT® (Skin Cancer Therapy) treatments in South Africa and subsequently service the African Continent.

Read More

OncoBeta GmbH® Announces Certification of its New Production Facility Partner MAP Medical Technologies Oy, Tikkakoski FINLAND

Garching n. Munich, Germany, (June 08, 2018) – OncoBeta GmbH has today announced the certification of its new production facility partner MAP Medical Technologies Oy, Tikkakoski FINLAND, aiming to deliver OncoBeta GmbH’s high-quality products to more patients in a timely manner as well as further address rising patients’ needs. MAP Medical Technologies is a GMP […]

Read More

Rhenium-SCT® (Skin Cancer Therapy) now being offered in Bologna, Italy

Garching n. Muenchen, Germany, (September 13, 2017) – OncoBeta® GmbH is privileged to announce the start of the next Rhenium-SCT® treatment center located in Bologna Italy. Prof. Stefano Fanti, Director of the Nuclear Medicine and his team are working close together with Prof. Annalisa Patrizi, Director of Dermatology and her team at the Policlinico S.Orsola […]

Read More

Shannon D. Brown III Appointed New Managing Director of OncoBeta GmbH

Garching b. Munich, Germany, (July 25, 2017) – OncoBeta GmbH has announced today that its board of directors has unanimously chosen Shannon D. Brown III as the organization’s new Managing Director. Brown, who currently serves as OncoBeta International’s vice president of global business development, will take over duties as of 01 Sep. 2017. “The board […]

Read More

Rhenium-SCT® Receives Positive Assessment from German Society of Nuclear Medicine (DGN)

Garching n. Munich, Germany, (July 13, 2017) – OncoBeta GmbH®, a commercial stage Medical Device Company specialized in innovative epidermal radioisotope therapies, is pleased to announce that the Rhenium-SCT® Received a Positive Assessment the from German Society of Nuclear Medicine (DGN e.V.) pertaining to their treatment of Non-Melanoma Skin Cancers with the Rhenium-SCT® Therapy. The […]

Read More

OncoBeta Speaks at the World Rhenium Congress

OncoBeta® GmbH is pleased to announce the acceptance of the invitation to speak at the World Rhenium Congress hosted by the Dept. of Nuclear Medicine, KMCH in Coimbatore, India. Dr. Thomas Wendler, one of the managing directors at OncoBeta will speak about their new therapy for Non-Melanoma Skin Cancer Rhenium-SCT®. The Rhenium-SCT® (Skin Cancer Treatment) […]

Read More

OncoBeta Receives Eurostars Grant

We are happy to announce that OncoBeta® GmbH Germany, Leiden University Medical Center Netherlands and Metaoptima Technology Inc. Canada have received the eurostars SkinHeal Grant. The three-year grant of 2,515,230.00 Euros for Medical device technology (instrumentation, medical imaging, radiology) development. The long-term goal is to heal the most common skin cancers (non-melanoma, NMSC) with a […]

Read More

OncoBeta receives Baymed Grant for Medical Technology

Baymed 2017, Garching, Germany. OncoBeta® GmbH is proud to announce recipience of the Bavarian research program “Medical Technology”, from the Bavarian Ministry of Economic Affairs and Media, Energy and Technology supports joint and cooperation projects for research and development work in the field of medical technology. Support is given to innovative R & D projects […]

Read More